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Abstract 
Sugars represent a readily available entry into the chiral pool and possess a multivalent 
functionality allowing specific functionalzation for attachment to scaffolds possessing 
programmed properties. We report a series of cyclometallated iridium(III) complexes 
[Ir(C^N)2(N^N)][PF6] in which a photo- and redox-active iridium scaffold is 
functionalized with ribofuranose substituents. The localization of HOMO and LUMO 
character in different parts of the iridium core is retained in the conjugates and proof-of-
concept compounds with the ribofuranose attached to the C^N and N^N ligands confirm 
that the photophysical and redox properties may be refined utilizing the well-established 
algorithms.   
  ____________________________________________ 
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1. Introduction 
Stereogenic ligands in metal complexes can play a number of crucial roles and one that 
is long investigated is in the generation of chiral reaction spaces for asymmetric 
catalysis [1,2,3]. Although many chiral ligands and complexes result from elegant 
design and synthetic strategies, the ready availability of enantiopure sugars from the 
chiral pool makes them attractive candidates for incorporation as stereogenic motifs. 
Typically, sugars contain multiple defined and enantiostable stereogenic centres together 
with less well defined stereochemistries at the anomeric centres. Peripheral sugar 
moieties as enantiopure substituents on ligands can be used for chiral induction at 
stereogenic metal centres in appropriate complexes [4]. Sugar functionalities are also of 
great interest in modifying the physicochemical properties of metal complexes, in 
particular the multiple hydroxy substiuents can dramatically increase the hydrophilicity 
of the compound, facilitating the use of such metal complexes in biological applications 
[5].  Finally, the introduction of biomotifs allows the use of such complexes for the 
delivery of unnatural functional properties to target cells or cell components using 
established biological molecular recognition strategies and offers new strategies for 
photodynamic therapies when the biomotifs are conjugated with photoactive centres. 
The conjugation of luminescent transition metal scaffolds with sugar domains has 
attracted some recent interest [6] with some focus on cyclometallated iridium(III) 
complexes [7,8,9,10,11] bearing . Colour tuning of [Ir(C^N)2(N^N)]+ complexes (C^N = 
cyclometallating ligand, N^N = chelating N,N'-donor) is facile and the localized nature 
of the highest-occupied and lowest-unoccupied molecular orbitals (HOMO and LUMO) 
in the ground state of the complex allows the two levels to be selectively addressed. 
Typically, the HOMO is localized on the {Ir(C^N)2} domain, whilst the LUMO is 
localized on the N^N ligand [12]. Thus, the emission energy can be tuned by 
modification of the C^N or the N^N  ligands to modify the HOMO and LUMO energy 
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levels respectively [12]. We have now extended our previous investigations in sugar-
functionalized oligopyridine ligands [4,13,14] to include their incorporation into 
emissive [Ir(C^N)2(N^N)]+ complexes. We present here an investigation of the 
syntheses, photophysical and electrochemical properties of a series of 
[Ir(C^N)2(N^N)]Cl complexes incorporating the ligands shown in Scheme 1.     
  
Scheme 1. Structures of the protected and deprotected sugar-functionalized ligands. For 
the ligand abbreviations, only the stereochemistry at the anomeric carbon atom is 
designated. Ring and atom labels for NMR spectroscopic assignments are shown. 
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2. Experimental 
2.1  General  
All starting materials were purchased as reagent grade and used as received. For 
reactions performed under inert atmosphere, dry solvents were obtained from Sigma-
Aldrich or Acros Organics. For all other reactions, solvents were of reagent grade or 
distilled. For analyses, HPLC grade solvents were used. Column chromatography was 
carried out with Silicycle silica gel (40–63 µm). Dowex 50WX4 was purchased from 
Fluka. 
NMR spectra were recorded on Bruker Avance III-400 (400 MHz) and III-500 
(500 MHz) spectrometers. Chemical shifts were referenced to residual solvent peaks 
with δ(TMS) = 0 ppm. Electrospray ionization mass spectra were measured on a Bruker 
esquire 3000plus or a Shimadzu LCMS-2020	 instrument and high resolution ESI mass 
spectra on a Bruker maXis 4G QTOF spectrometer. LC-ESI mass spectrometry was 
carried out on a combination of Shimadzu (LC) and Bruker AmaZon X instruments. 
Absorption spectra were obtained on an Agilent 8453 spectrophotometer and emission 
spectra on a Shimadzu 5301PC spectrofluorophotometer. Photoluminescence quantum 
yields were measured on a Hamamatsu absolute PL quantum yield spectrometer C11347 
Quantaurus QY and excited-state lifetime measurements were performed on a 
Hamamatsu Compact Fluorescence lifetime spectrometer C11367 Quantaurus Tau.  
Electrochemical measurements were carried out using a CH Instruments 900B 
potentiostat using propylene carbonate solutions of complexes with [nBu4N][PF6] (0.1 
M) as supporting electrolyte and at a scan rate of 0.1 V s–1. The working electrode was 
glassy carbon, the reference electrode was a leakless Ag+/AgCl (eDAQ  ET069-1) and 
the counter-electrode a Pt wire. Final potentials were referenced with respect to the 
Fc/Fc+ couple.  
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4,4'-Dihydroxy-2,2'-bipyridine [15], 2-(4-hydroxyphenyl)pyridine [16], 2-
bromoethyl-2,3,5-triacetyl-β-D-ribofuranoside [4,13], (R)-1 [4] and [Ir(ppy)2Cl]2 [17,18] 
were synthesized following literature procedures. 2-Bromoethyl-2,3,5-triacetyl-α-D-
ribofuranoside was obtained as a side product in 9.1% yield from the synthesis of 2-
bromoethyl-2,3,5-triacetyl-β-D-ribofuranoside [4,13].   
 
2.2 (S)-1 
4,4'-Dihydroxy-2,2'-bipyridine (30.5 mg, 0.162 mmol, 0.54 eq.) and K2CO3 (127 mg, 
0.919 mmol, 3.0 eq.) were suspended in dry DMF (2.5 mL) under a nitrogen atmosphere 
and heated to 75 °C. After 45 min, a solution of 2-bromoethyl-2,3,5-triacetyl-α-D-
ribofuranoside (116 mg, 0.303 mmol, 1.0 eq.) in dry DMF (2.5 mL) and KI (50.2 mg, 
0.302 mmol, 1.0 eq.) were added and heated at 75 °C overnight. The mixture was left to 
cool to room temperature and the solvent evaporated under reduced pressure. The 
residue was suspended in H2O and extracted with CH2Cl2 (3×20 mL). The combined 
organic layers were dried over Na2SO4 and the solvent removed under reduced pressure. 
The crude product was purified by column chromatography (SiO2, CH2Cl2–8% MeOH) 
to yield (S)-1 as a colourless oil (94.6 mg, 0.119 mmol, 78.5%). 1H NMR (500 MHz, 
CDCl3) δ/ppm 8.46 (d, J = 5.6 Hz, 2H, HC6), 7.98 (d, J = 2.6 Hz, 2H, HC3), 6.86 (dd, J = 
5.7, 2.6 Hz, 2H, HC5), 5.37 (d, J = 4.5 Hz, 2H, HS1), 5.17 (dd, J = 7.4, 4.0 Hz, 2H, HS3), 
4.97 (dd, J = 7.4, 4.5 Hz, 2H, HS2), 4.39–4.28 (m, 8H, HS4+a+a’+c), 4.21 (dd, J = 11.9, 4.1 
Hz, 2H, Hc’), 4.10 (ddd, J = 11.6, 5.3, 3.7 Hz, 2H, Hb), 3.94 (ddd, J = 11.5, 6.5, 3.7 Hz, 
2H, Hb’), 2.09 (s, 6H, HS3-OAc/c-OAc), 2.08 (s, 6H, HS3-OAc/c-OAc), 2.05 (s, 6H, HS2-OAc). 13C 
NMR (126 MHz, CDCl3) δ/ppm 170.5 (2C, CS3-C(O)+c-C(O)), 169.9 (CS2-C(O)), 165.9 (CC4), 
157.8 (CC2), 150.2 (CC6), 111.4 (CC5), 106.6 (CC3), 100.8 (CS1), 79.5 (CS4), 70.9 (CS2), 
69.9 (CS5), 67.1 (Ca), 66.5 (Cb), 63.5 (Cc), 21.0 (CS3-OAc/c-OAc), 20.9 (CS3-OAc/c-OAc), 20.6 
(CS2-OAc). LC-ESI MS m/z 793.3 [M+H]+ (calc. 793.3). 
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2.3 H{(R)-2}  
2-(4-Hydroxyphenyl)pyridine (67.8 mg, 0.396 mmol, 1.0 eq.) and K2CO3 (164 mg, 1.18 
mmol, 3.0 eq.) were suspended in dry DMF (2.5 mL) under a nitrogen atmosphere and 
heated to 75 °C. After 45 min, a solution of 2-bromoethyl-2,3,5-triacetyl-β-D-
ribofuranoside (152 mg, 0.397 mmol, 1.0 eq.) in dry DMF (2.5 mL) and KI (66.4 mg, 
0.400 mmol, 1.0 eq.) were added and stirred overnight at 75 °C. The mixture was left to 
cool to room temperature and the solvent was evaporated under reduced pressure. The 
residue was suspended in H2O (20 mL) and extracted with CH2Cl2 (3×20 mL). The 
combined organic layers were dried over Na2SO4 and the solvent was removed under 
reduced pressure. The crude product was purified by column chromatography (SiO2, 
EtOAc/cyclohexane 1:1) to yield H{(R)-2} as a colourless oil (150 mg, 0.317 mmol, 
80.0%). 1H NMR (500 MHz, CDCl3) δ/ppm 8.64 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H, HB6), 
7.97–7.91 (m, 2H, HA3), 7.71 (ddd, J = 8.1, 7.3, 1.8 Hz, 1H, HB4), 7.66 (dt, J = 8.1, 1.2 
Hz, 1H, HB3), 7.17 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H, HB5), 7.02–6.97 (m, 2H, HA2), 5.36 
(dd, J = 6.7, 4.9 Hz, 1H, HS3), 5.31 (dd, J = 4.9, 0.9 Hz, 1H, HS2), 5.13 (s, 1HS1), 4.39–
4.30 (m, 2H, HS4+c), 4.21–4.14 (m, 3H, Ha+a’+c'), 4.07 (dt, J = 11.1, 4.5 Hz, 1H, Hb), 3.85 
(dt, J = 11.0, 4.8 Hz, 1H, Hb’), 2.11 (s, 3H, HS2-OAc), 2.08 (s, 3H, Hc-OAc), 2.05 (s, 3H, 
HS3-OAc). 13C NMR (126 MHz, CDCl3) δ/ppm 170.8 (Cc-C(O)), 169.80 (CS3-C(O)), 169.75 
(CS2-C(O)), 159.6 (CA1), 157.2 (CB1), 149.7 (CB6), 136.8 (CB4), 132.5 (CA4), 128.3 (CA3), 
121.6 (CB5), 120.0 (CB3), 114.9 (CA2), 105.6 (CS1), 78.9 (CS4), 74.9 (CS2), 71.7 (CS3), 
67.1 (Ca), 66.5 (Cb), 64.9 (Cc), 21.0 (Cc-OAc), 20.8 (CS2-OAc), 20.7 (CS3-OAc). LC-ESI MS 
m/z 474.2 [M+H]+ (calc. 474.2). 
 
2.4 [Ir{(R)-2}2Cl]2 
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H{(R)-2} (147 mg, 310 µmol, 1.0 eq.) was dissolved in 2-ethoxyethanol (3 mL) under 
nitrogen atmosphere. [Ir(cod)Cl]2 (52.3 mg, 77.9 µmol, 0.25 eq.) was added and the 
mixture was heated at reflux overnight. A few drops of H2O were added and the 
resulting orange precipitate was filtered off, washed with EtOH and Et2O and 
redissolved in CH2Cl2. The solvent was removed under reduced pressure to yield 
[Ir{(R)-2}2Cl]2 as an orange solid which was used for subsequent transformations 
without further purification (70.6 mg, 30.1 µmol, 38.8%). 1H NMR (400 MHz, CDCl3) 
δ/ppm 9.14 (tt, J = 4.0, 1.1 Hz, 4H), 7.81–7.66 (m, 8H), 7.40 (d, J = 8.7 Hz, 4H), 6.74–
6.68 (m, 4H), 6.34 (dd, J = 8.5, 2.5 Hz, 4H), 5.39 (t, J = 2.8 Hz, 4H), 5.26 (dd, J = 6.7, 
4.9 Hz, 4H), 5.18 (ddd, J = 4.7, 3.3, 0.9 Hz, 4H), 4.96 (d, J = 1.9 Hz, 4H), 4.32–4.20 (m, 
8H), 4.03 (ddd, J = 11.5, 5.9, 2.6 Hz, 4H), 3.81–3.71 (m, 4H), 3.66 (q, J = 3.7, 2.5 Hz, 
8H), 3.56 (dt, J = 10.2, 4.9 Hz, 4H), 2.06 (s, 6H), 2.06 (s, 6H), 2.03 (s, 6H), 2.02 (s, 6H), 
1.99 (s, 6H), 1.97 (s, 6H). LC-ESI-MS m/z 1137.3	[Ir(C^N)2]+ (calc. 1137.3). 
 
2.5 General Procedure for the Synthesis of Ir(III) Complexes  
Chlorido-bridged Ir(III) dimer and N^N ligand were suspended in MeOH (5 mL) and 
heated at reflux overnight. The suspension was left to cool to room temperature, filtered 
through Celite®, washed with MeOH and the filtrate was concentrated under reduced 
pressure. The crude product was purified by column chromatography (SiO2, CH2Cl2–
MeOH) to yield the desired product. 
 
2.6 [Ir(ppy)2{(R)-1}]Cl 
[Ir(ppy)2Cl]2 (56.0 mg, 52.2 µmol, 0.51 eq.) and (R)-1 (82.0 mg, 103 µmol, 1.0 eq.). 
Purification by column chromatography with CH2Cl2–10% MeOH gave [Ir(ppy)2{(R)-
1}]Cl as a yellow solid (122 mg, 91.8 µmol, 88.8%). 1H NMR (500 MHz, CD3CN) 
δ/ppm 8.30 (m, 2H, HC3), 8.05 (dt, J = 8.2, 1.0 Hz, 2H, HB3), 7.86–7.80 (m, 2H, HB4), 
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7.78 (dd, J = 8.0, 1.3 Hz, 2H, HA3), 7.70 (d, J = 6.4 Hz, 2H, HC6), 7.69–7.67 (m, 2H, 
HB6), 7.05 (ddd, J = 7.4, 5.8, 1.4 Hz, 2H, HB5), 7.02–6.99 (m, 4H, HA4+C5), 6.88 (td, J = 
7.4, 1.3 Hz, 2H, HA5), 6.27 (dd, J = 7.6, 1.2 Hz, 2H, HA6), 5.17 (dd, J = 6.5, 4.7 Hz, 2H, 
HS3), 5.14–5.09 (m, 4H, HS1+S2), 4.50–4.40 (m, 4H, Ha+a’), 4.31–4.25 (m, 4H, HS4+c), 
4.12–4.07 (m, 2H, Hc’), 4.07–4.00 (m, 2H, Hb), 3.87–3.80 (m, 2H, Hb’), 2.05 (s, 3H, Hc-
OAc), 2.04 (s, 3H, Hc-OAc*), 2.00 (s, 6H, HS3-OAc), 1.98 (s, 3H, HS2-OAc), 1.97 (s, 3H, HS2-
OAc*). 13C NMR (126 MHz, CD3CN) δ/ppm 171.50 (Cc-C(O)), 171.49 (Cc-C(O)*), 170.8 
(CS3-C(O)), 170.64 (CS2-C(O)), 170.63 (CS2-C(O)*), 168.4 (CB2), 168.0 (CC4), 158.4 (CC2), 
152.2 (CC6), 151.8 (CA1), 150.0 (CB6), 145.1 (CA2), 139.2 (CB4), 132.5 (CA6), 131.2 
(CA5), 125.7 (CA3), 124.3 (CB5), 123.2 (CA4), 120.6 (CB3), 115.4 (CC5), 112.81 (CC3), 
112.79 (CC3*), 106.01 (CS1), 105.97 (CS1*), 79.4 (CS4), 75.1 (CS2), 72.6 (CS3), 69.8 (Ca), 
66.5 (Cb), 66.4 (Cb*), 65.60 (Cc), 65.57 (Cc*), 21.0 (CS2-OAc), 20.73 (Cc-OAc), 20.66 (CS3-
OAc). ESI MS m/z 1293.8 [M–Cl]+ (calc. 1293.4). HR ESI-MS m/z 1293.3537 [M–Cl]+ 
(calc. 1293.3531). UV-Vis (MeOH, 1.0 × 10−5 M) λ/nm (ε/dm3 mol−1 cm−1) 223 (50 500), 
255 (57 700), 300 sh (21 400), 342 sh (9600), 412 sh (3700). Emission (MeOH, 1.0 × 
10−5 M, λexc = 380 nm) λemmax = 571 nm. 
 
2.7 [Ir(ppy)2{(S)-1}]Cl 
[Ir(ppy)2Cl]2 (64.0 mg, 59.7 µmol, 0.51 eq.) and (S)-1 (93.3 mg, 118 µmol, 1.0 eq.). 
Purification by column chromatography with CH2Cl2–10% MeOH gave [Ir(ppy)2{(S)-
1}]Cl as a yellow solid (123 mg, 92.6 µmol, 78.2%). 1H NMR (500 MHz, CD3CN) 
δ/ppm 8.11 (dd, J = 2.5, 1.7 Hz, 2H, HC3), 8.05 (dt, J = 8.2, 1.2 Hz, 2H, HB3), 7.84 (ddd, 
J = 8.3, 7.5, 1.5 Hz, 2H, HB4), 7.78 (dd, J = 7.9, 1.2 Hz, 2H, HA3), 7.73 (dd, J = 6.4, 2.4 
Hz, 2H, HC6), 7.65 (dddd, J = 7.3, 5.9, 1.6, 0.7 Hz, 2H, HB6), 7.09–7.00 (m, 6H, 
HA4+B5+C5), 6.89 (td, J = 7.4, 1.3 Hz, 2H, HA5), 6.27 (ddd, J = 7.7, 2.4, 1.2 Hz, 2H, HA6), 
5.29 (t, J = 4.5 Hz, 2H, HS1), 5.09 (dd, J = 7.4, 4.2 Hz, 2H, HS3), 4.96 (ddd, J = 9.8, 7.4, 
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4.5 Hz, 2H, HS2), 4.40 (dt, J = 7.1, 3.8 Hz, 4H, Ha+a’), 4.26 (dd, J = 11.9, 3.2 Hz, 2H, 
Hc), 4.21 (dtd, J = 7.7, 4.4, 3.2 Hz, 2H, HS4), 4.12 (dt, J = 11.8, 4.3 Hz, 2H, Hc’), 4.07–
4.00 (m, 2H, Hb), 3.93–3.85 (m, 2H, Hb’), 1.99 (s, 3H, Hc-OAc), 1.98 (s, 3H, Hc-OAc*), 1.92 
(s, 3H, HS3-OAc), 1.91 (s, 3H, HS3-OAc*), 1.90 (s, 3H, HS2-OAc), 1.80 (s, 3H, HS2-OAc*). 13C 
NMR (126 MHz, CD3CN) δ/ppm 171.3 (Cc-C(O)), 171.0 (CS3-C(O)), 170.51 (CS2-C(O)), 
170.45 (CS2-C(O)*), 168.55 (CB2), 168.53 (CB2*), 168.14 (CC4), 168.10 (CC4*), 158.3 (CC2), 
152.4 (CC6), 151.7 (CA1), 149.9 (CB6), 145.1 (CA2), 139.3 (CB4), 132.53 (CA6), 132.50 
(CA6*), 131.2 (CA5), 125.8 (CA3), 124.3 (CB5), 123.3 (CA4), 120.7 (CB3), 115.43 (CC5), 
115.40 (CC5*), 112.8 (CC3), 101.7 (CS1), 101.6 (CS1*), 80.3 (CS4), 71.5 (CS2), 70.4 (CS3), 
70.14 (Ca), 70.10 (Ca*), 66.9 (Cb), 64.1 (Cc), 20.90 (Cc-OAc), 20.89 (Cc-OAc*), 20.85 (CS3-
OAc), 20.8 (CS3-OAc*), 20.6 (CS2-OAc), 20.5 (CS2-OAc*). ESI MS m/z 1293.7 [M–Cl]+ (calc. 
1293.4). HR ESI MS m/z 1293.3541 [M–Cl]+ (calc. 1293.3531). UV-Vis (MeOH, 1.0 × 
10−5 M) λ/nm (ε/dm3 mol−1 cm−1) 223 (48 700), 255 (55 100), 300 sh (21 000), 342 sh 
(9400), 412 sh (3300). Emission (MeOH, 1.0 × 10−5 M, λexc = 380 nm) λemmax = 576 nm. 
  
2.8 [Ir{(R)-2}2(bpy)]Cl  
[Ir{(R)-2}2Cl]2 (70.6 mg, 30.1 µmol, 1.0 eq.) and bpy (10.2 mg, 65.3 µmol, 2.2 eq.). 
Purification by column chromatography with CH2Cl2–10% MeOH changing to CH2Cl2–
20% MeOH gave [Ir{(R)-2}2(bpy)]Cl as a yellow solid (36.7 mg, 27.6 µmol, 45.9%). 1H 
NMR (500 MHz, CD3CN) δ/ppm 8.59 (d, J = 8.0 Hz, 2H, HC3), 8.13 (td, J = 7.9, 1.7 Hz, 
2H, HC4), 8.04 (dt, J = 5.3, 1.8 Hz, 2H, HC6), 7.93 (dt, J = 8.3, 1.1 Hz, 2H, HB3), 7.81–
7.71 (m, 4H, HA3+B4), 7.56–7.48 (m, 4H, HB6+C5), 6.93 (dddd, J = 7.3, 5.8, 2.7, 1.4 Hz, 
2H, HB5), 6.63 (ddd, J = 8.7, 2.6, 0.9 Hz, 2H, HA4), 5.72 (dd, J = 2.6, 1.4 Hz, 2H, HA6), 
5.15 (ddd, J = 6.7, 4.9, 2.8 Hz, 2H, HS3), 5.09 (dd, J = 4.9, 1.0 Hz, 2H, HS2), 5.01 (t, J = 
1.0 Hz, 2H, HS1), 4.30–4.20 (m, 4H, HS4+c), 4.01 (dt, J = 11.5, 5.5 Hz, 2H, Hc’), 3.90 
(ddd, J = 7.6, 5.8, 3.6 Hz, 4H, Ha+a’), 3.87–3.81 (m, 2H, Hb), 3.63 (dtd, J = 11.5, 6.0, 3.2 
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Hz, 2H, Hb’), 2.05 (s, 3H, HS2-OAc), 2.04 (s, 3H, HS2-OAc*), 2.00 (s, 3H, HS3-OAc), 2.00 (s, 
3H, HS3-OAc*), 1.96 (s, 3H, Hc-OAc), 1.94 (s, 3H, Hc-OAc*). 13C NMR (126 MHz, CD3CN) 
δ/ppm 171.27 (Cc-C(O)), 171.25 (Cc-C(O)*), 170.9 (CS3-C(O)), 170.6 (CS2-C(O)), 168.07 (CB2), 
168.05 (CB2*), 161.16 (CA5), 161.15 (CA5*), 156.7 (CC2), 153.7 (CA1), 153.6 (CA1*), 151.7 
(CC6), 149.9 (CB6), 140.3 (CC4), 139.3 (CB4), 138.00 (CA2), 137.98 (CA2*), 129.3 (CC5), 
127.6 (CA3), 125.7 (CC3), 123.20 (CB5), 123.18 (CB5*), 120.1 (CB3), 118.0 (CA6), 117.9 
(CA6*), 109.2 (CA4), 109.0 (CA4*), 106.0 (CS1), 105.9 (CS1*), 79.4 (CS4), 79.3 (CS4*), 
75.19 (CS2), 75.18 (CS2*), 72.3 (CS3), 72.2 (CS3*), 67.39 (Ca), 67.37 (Ca*), 66.94 (Cb), 
66.85 (Cb*), 65.0 (Cc), 64.8 (Cc*), 21.00 (Cc-OAc), 20.98 (Cc-OAc*), 20.75 (CS2-OAc), 20.74 
(CS2-OAc*), 20.69 (CS3-OAc). ESI MS m/z 1293.2 [M–Cl]+ (calc. 1293.4). HR ESI-MS m/z 
1293.3535 (calc. 1293.3526). UV-Vis (MeOH, 1.0 × 10−5 M) λ/nm (ε/dm3 mol−1 cm−1) 
253 (47 300), 276 (55 500), 310 sh (36 300), 370 sh (10 700). Emission (MeOH, 1.0 × 
10−5 M, λexc = 380 nm) λemmax = 588 nm. 
 
2.9 General procedure for deprotection of acetyl-protected Ir(III) complexes 
NaOMe was added to a solution of acetyl-protected Ir(III) complex in MeOH (2–10 mL) 
and stirred at room temperature for 4–8 h. Acidic DOWEX 50WX4 (pre-washed with 
H2O, 1 M HCl, H2O, MeOH) was added and the mixture was stirred at room temperature 
for 30 min. The mixture was filtered through Celite® and the filtrate was concentrated 
under reduced pressure. The residue was washed with acetone and dried under vacuum 
to yield the desired product. 
 
2.10 [Ir(ppy)2{(R)-3}]Cl  
[Ir(ppy)2{(R)-1}]Cl (122 mg, 91.8 µmol, 1.0 eq.) and NaOMe (5.30 mg, 96.1 µmol, 1.1 
eq.) in MeOH (10 mL), stirring for 4 h. [Ir(ppy)2{(R)-3}]Cl was obtained as a yellow 
solid (97.4 mg, 90.5 µmol, 98.6%). 1H NMR (500 MHz, DMSO-d6) δ/ppm 8.49 (t, J = 
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2.9 Hz, 2H, HC3), 8.24 (dt, J = 8.3, 1.0 Hz, 2H, HB3), 7.95–7.91 (m, 2H, HB4), 7.89 (dd, J 
= 7.8, 1.3 Hz, 2H, HA3), 7.71–7.64 (m, 2H, HB6), 7.59 (d, J = 6.4 Hz, 2H, HC6), 7.28 (dd, 
J = 6.5, 2.6 Hz, 2H, HC5), 7.18 (ddd, J = 7.3, 5.7, 1.4 Hz, 2H, HB5), 6.99 (td, J = 7.5, 1.2 
Hz, 2H, HA4), 6.87 (td, J = 7.4, 1.3 Hz, 2H, HA5), 6.19 (dd, J = 7.6, 1.2 Hz, 2H, HA6), 
4.83 (s, 2H, HS1), 4.43–4.31 (m, 4H, Ha+a’), 3.96 (ddd, J = 11.9, 5.1, 3.1 Hz, 2H, Hb), 
3.86–3.80 (m, 2H, HS3), 3.80–3.72 (m, 4H, HS4+b’), 3.71 (dt, J = 4.7, 1.2 Hz, 2H, HS2), 
3.51 (dt, J = 11.6, 3.9 Hz, 2H, Hc), 3.33 (dt, J = 11.6, 5.9 Hz, 8H, Hc’+S2-OH+S3-OH+c-OH). 
13C NMR (126 MHz, DMSO-d6) δ/ppm 166.9 (CB2), 166.2 (CC4), 156.9 (CC2), 151.1 
(CA1), 150.5 (CC6), 148.8 (CB6), 143.9 (CA2), 138.5 (CB4), 131.2 (CA6), 130.1 (CA5), 
125.0 (CA3), 123.8 (CB5), 122.0 (CA4), 119.9 (CB3), 114.9 (CC5), 111.9 (CC3), 106.89 
(CS1), 106.87 (CS1*), 83.8 (CS4), 74.3 (CS2), 70.9 (CS3), 68.7 (Ca), 64.5 (Cb), 63.0 (Cc). 
ESI MS m/z 1041.2 [M–Cl]+ (calc. 1041.3). HR ESI-MS m/z 1041.2887 [M–Cl]+ (calc. 
1041.2896). UV-Vis (MeOH, 1.0 × 10−5 M) λ/nm (ε/dm3 mol−1 cm−1) 223 (48 300), 255 
(55 800), 300 sh (21 100), 342 sh (9600), 412 sh (3500). Emission (MeOH, 1.0 × 10−5 
M, λexc = 380 nm) λemmax = 572 nm. 
 
2.11 [Ir(ppy)2{(S)-3}]Cl 
[Ir(ppy)2{(S)-1}]Cl (70.0 mg, 52.7 µmol, 1.0 eq.) and NaOMe (2.90 mg, 52.7 µmol, 1.0 
eq.) in MeOH (6 mL), stirring for 5 h. [Ir(ppy)2{(S)-3}]Cl was obtained as a yellow 
solid (54.9 mg, 51.0 µmol, 96.8%). 1H NMR (500 MHz, DMSO-d6) δ/ppm 8.50 (s, 2H, 
HC3), 8.24 (dt, J = 8.3, 0.9 Hz, 2H, HB3), 7.94–7.90 (m, 2H, HB4), 7.89 (dd, J = 8.0, 1.3 
Hz, 2H, HA3), 7.70–7.65 (m, 2H, HB6), 7.59 (d, J = 6.4 Hz, 2H, HC6), 7.29 (dd, J = 6.5, 
2.6 Hz, 2H, HC5), 7.18 (ddd, J = 7.3, 5.8, 1.4 Hz, 2H, HB5), 6.99 (td, J = 7.5, 1.2 Hz, 2H, 
HA4), 6.87 (td, J = 7.5, 1.3 Hz, 2H, HA5), 6.19 (dd, J = 7.6, 1.2 Hz, 2H, HA6), 4.95 (dd, J 
= 4.4, 1.1 Hz, 2H, HS1), 4.72 (br, 2H, Hc-OH), 4.57 (br, 2H, HS3-OH), 4.48–4.36 (m, 4H, 
Ha+a’), 4.17 (br, 2H, HS2-OH), 4.02–3.93 (m, 2H, Hb), 3.89–3.78 (m, 6H, HS2+S4+b’), 3.78–
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3.72 (br, 2H, HS3), 3.45–3.36 (br, 4H, Hc+c’). 13C NMR (126 MHz, DMSO-d6) δ/ppm 
166.9 (CB2), 166.7 (CC4), 156.9 (CC2), 151.0 (CA1), 150.3 (CC6), 148.6 (CB6), 143.8 (CA2), 
138.4 (CB4), 131.0 (CA6), 129.9 (CA5), 124.9 (CA3), 123.7 (CB5), 121.8 (CA4), 119.7 
(CB3), 114.7 (CC5), 111.7 (CC3), 101.7 (CS1), 84.9 (CS4), 70.9 (CS2), 69.0 (CS3), 68.7 (Ca), 
65.1 (Cb), 61.4 (Cc). ESI MS m/z 1041.1 [M–Cl]+ (calc. 1041.3). HR ESI-MS m/z 
1041.2897 (calc. 1041.2896). UV-Vis (MeOH, 1.0 × 10−5 M) λ/nm (ε/dm3 mol−1 cm−1) 
223 (48 200), 255 (55 600), 300 sh (21 200), 342 sh (9700), 412 sh (3600). Emission 
(MeOH, 1.0 × 10−5 M, λexc = 380 nm) λemmax = 572 nm. 
 
2.12 [Ir{(R)-4}2(bpy)]Cl  
[Ir{(R)-2}2(bpy)]Cl (18.4 mg, 13.8 µmol, 1.0 eq.) and NaOMe (0.84 mg, 15.2 µmol, 1.1 
eq.) in MeOH (2 mL), stirring for 8 h. [Ir{(R)-4}2(bpy)]Cl was obtained as a yellow 
solid (12.4 mg, 11.5 µmol, 83.5%). 1H NMR (500 MHz, DMSO-d6) δ/ppm 8.88 (d, J = 
8.2 Hz, 2H, HC3), 8.27 (td, J = 7.9, 1.6 Hz, 2H, HC4), 8.13 (d, J = 8.3 Hz, 2H, HB3), 7.93 
(ddd, J = 5.3, 3.5, 1.5 Hz, 2H, HC6), 7.90–7.83 (m, 4H, HA3+B4), 7.71 (ddd, J = 7.9, 5.5, 
1.3 Hz, 2H, HC5), 7.51 (dd, J = 5.8, 1.6 Hz, 2H, HB6), 7.06 (ddd, J = 7.3, 5.7, 1.4 Hz, 2H, 
HB5), 6.65 (ddd, J = 8.6, 2.7, 1.1 Hz, 2H, HA4), 5.63 (d, J = 2.4 Hz, 2H, HA6), 5.03 (br, 
2H, HS2-OH), 4.85 (br, 2H, HS3-OH), 4.74 (s, 2H, HS1), 4.52 (br, 2H, Hc-OH), 3.94–3.71 (m, 
10H, HS3+S4+a+a’+b), 3.68 (d, J = 4.0 Hz, 2H, HS2), 3.60–3.52 (m, 2H, Hb’), 3.50–3.44 (m, 
2H, Hc), 3.31–3.28 (br, 2H, Hc’). 13C NMR (126 MHz, DMSO-d6) δ/ppm 166.6 (CB2), 
159.7 (CA5), 155.4 (CC2), 152.6 (CA1), 149.9 (CC6), 148.4 (CB6), 139.6 (CC4), 138.5 (CB4), 
136.7 (CA2), 128.6 (CC5), 126.7 (CA3), 124.9 (CC3), 122.4 (CB5), 119.2 (CB3), 117.0 
(CA6), 107.4 (CA4), 106.8 (CS1), 83.6 (CS4), 74.2 (CS2), 70.7 (CS3), 66.1 (Ca), 64.8 (Cb), 
62.9 (Cc). ESI MS m/z 1041.2 [M–Cl]+ (calc. 1041.3). HR ESI-MS m/z 1041.2889 [M-
Cl]+ (calc. 1041.2896). UV-Vis (MeOH, 1.0 × 10−5 M) λ/nm (ε/dm3 mol−1 cm−1) 254 
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(44100), 276 (52 000), 310 sh (33 300), 370 sh (9700). Emission (MeOH, 1.0 × 10−5 M, 
λexc = 380 nm) λemmax = 589 nm. 
3 Results and discussion 
3.1 Ligand synthesis  
For these proof of concept studies, we selected protected and deprotected sugars in the 
pentose series as these are both readily accessible and robust. We have previously 
described the synthesis of the acetyl-protected ribofuranose-functionalized bpy ligand 
(R)-1 (Scheme 1) [4], and the anomeric ligand (S)-1 was prepared by an analogous route 
as shown in the first step in Scheme 2 (we use an abbreviated stereochemical 
nomenclature to indicate the stereochemistry at the anomeric centre). A parent peak at 
m/z 793.3 in the LC-ESI mass spectrum of (S)-1 was assigned to the [M+H]+ ion. The 
solution 1H and 13C NMR spectra of (S)-1 were consistent with a symmetrical 
substitution pattern of the bpy metal-binding domain, and were fully assigned using 
COSY, HMQC and HMBC methods; ring and atom labelling is shown in Scheme 1. The 
signal for proton HS1 at the anomeric centre appears as a singlet in (R)-1 (β-
configuration) [4] and as a doublet (J = 4.5 Hz) in (S)-1 (α-configuration) with the 
difference in the 3J coupling constant following the expected trend from the Karplus 
equation [19]. The 2-phenylpyridine derivative H{(R)-2} was prepared as shown in 
Scheme 3, following a similar approach to that used for (R)-1. In the LC-ESI mass 
spectrum, a peak at m/z = 474.2 was assigned to the [M+H]+ ion. The solution 1H and 
13C NMR spectra were fully assigned by 2D methods, and retention of stereochemistry 
at the anomeric position (β-configuration) was confirmed by the observation of a singlet 
for proton HS1.   
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Scheme 2. Synthetic route adopted for the ribofuranose-functionalized complexes 
[Ir(ppy)2{(S)-1}]Cl and [Ir(ppy)2{(S)-3}]Cl. 
 
3.2 Synthesis of [Ir(ppy)2{(S)-1}]Cl, [Ir(ppy)2{(R)-1}]Cl, [Ir(ppy)2{(S)-3}]Cl and 
[Ir(ppy)2{(R)-3}]Cl 
The standard methodology for the preparation of cyclometallated [Ir(C^N)2(N^N)]+ 
complexes is the treatment of a dichlorido-bridged dimer [Ir(C^N)2Cl]2 with an 
appropriate N^N ligand [17,18]. In this work, two types of [Ir(C^N)2(N^N)]+ complexes 
have been prepared, the first with the ribofuranose-functionality on the N^N bpy ligand 
and the second with the sugar attached to the  C^N cyclometallating ligand. For the 
synthesis of the first series of compounds, the enantiomerically pure ligands (S)-1 and 
(R)-1 were reacted with [Ir(ppy)2Cl]2 (Scheme 2) and the products [Ir(ppy)2{(S)-1}]Cl 
and [Ir(ppy)2{(R)-1}]Cl were obtained in 78.2 and 88.8% yields, respectively. The high-
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resolution electrospray mass spectra of [Ir(ppy)2{(S)-1}]Cl and [Ir(ppy)2{(R)-1}]Cl 
showed, respectively, peak envelopes at m/z 1293.3541 and 1293.3537, arising from the 
[M–Cl]+ ion. 
COSY, HMQC and HMBC techniques were used to assign the 1H and 13C NMR 
spectra of [Ir(ppy)2{(S)-1}]Cl and [Ir(ppy)2{(R)-1}]Cl. The 1H and 13C NMR spectra are 
given in Figs. S1–S4. The presence of the stereogenic {Ir(trischelate)} centre leads to 
each of [Ir(ppy)2{(S)-1}]+ and [Ir(ppy)2{(R)-1}]+ existing as a mixture of Δ and Λ 
diastereoisomers [20]. Typically, two signals were observed in the 13C NMR spectra for 
nuclei close to the anomeric centre of the acetyl-protected ribofuranose functionality 
(Fig. 1). In the experimental section and in Fig. 1, these are distinguished by use of an 
asterisk, although we note that the set of signals marked with asterisks do not necessarily 
belong to the diastereoisomers with the same absolute Δ or Λ configurations. The 
relative intensities of the signals for the pairs Cb/b*, Cc/c*, CS1/S1* and CC3/C3* confirm a 
statistical 1:1 mixture of Δ or Λ diastereoisomers. The acetyl protecting groups are 
characterized by six singlets in [Ir(ppy)2{(S)-1}]Cl arising from the two 
diastereoisomers. In the 13C NMR spectrum of [Ir(ppy)2{(R)-1}]Cl, the acetyl groups 
give rise only to five signal, since there is no separation of the signals arising from the 
acetyl groups attached to CS3 and CS3*. 
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Fig. 1. Parts of the 126 MHz 13C{1H} NMR spectrum of [Ir(ppy)2{(R)-1}]Cl (in 
CD3CN) showing distinction between Δ or Λ diastereoisomers for 13C nuclei b, c, S1 
and C3 (see Scheme 1 for numbering). 
 
Deprotection of [Ir(ppy)2{(R)-1}]Cl and [Ir(ppy)2{(S)-1}]Cl was carried out using 
NaOMe [13] followed by treatment with acidic Dowex ion exchange resin to give 
[Ir(ppy)2{(R)-3}]Cl and [Ir(ppy)2{(S)-3}]Cl. NMR spectra of the products are given in 
Figs. S5–S8. Complete loss of the acetyl groups was confirmed by the disappearance of 
all the signals in the range δ 1.97–2.05 ppm. Figure 2 compares the solution 1H NMR 
spectra of [Ir(ppy)2{(S)-1}]Cl and [Ir(ppy)2{(S)-3}]Cl; for reasons of solubility, a 
common solvent could not be used. As expected, resonances in the aliphatic region are 
the most affected. The 13C NMR spectra of DMSO-d6 solutions of the compounds were 
not as well resolved as those of the acetyl-protected analogs, and the only signal that 
showed a distinction between the Δ or Λ diastereoisomers was that for CS1 in 
[Ir(ppy)2{(R)-3}]Cl (signals at δ 106.89 and 106.87 ppm). The ESI mass spectra of 
 17 
[Ir(ppy)2{(R)-3}]Cl and [Ir(ppy)2{(S)-3}]Cl exhibited peak envelopes centred at m/z 
1041.2 and 1041.1, respectively. The isotope patterns matched those simulated for the 
[Ir(ppy)2{(R)-3}]+ or [Ir(ppy)2{(S)-3}]+ ions.   
 
Fig. 2. Comparison of the parts of the 500 MHz 1H NMR spectra of (a) [Ir(ppy)2{(S)-
1}]Cl in CD3CN, and (b) [Ir(ppy)2{(S)-3}]Cl in DMSO-d6. × = residual CH2Cl2. 
 
3.2 Synthesis of [Ir{(R)-2}2(bpy)]Cl and [Ir{(R)-4}2(bpy)]Cl  
For the synthesis of complexes with the ribofuranose-functionality appended to the 
cyclometallating ligand, it was first necessary to prepare the dinuclear complex [Ir{(R)-
2}2Cl]2. Most often, [Ir(C^N)2Cl]2 dimers are synthesized by treating IrCl3·xH2O with 
the appropriate H(C^N) ligand under reflux conditions [18]. However, an alternative 
approach starting from [Ir(cod)Cl]2 [21, 22] (cod = cycloocta-1,5-diene) is sometimes 
more convenient and this proved to be the case for [Ir{(R)-2}2Cl]2 which was prepared 
in a one-pot quadruple cyclometallation reaction of [Ir(cod)Cl]2 with H{(R)-2} (Scheme 
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3). In the LC-ESI mass spectrum of [Ir{(R)-2}2Cl]2, a peak envelope at m/z 1137.3 was 
observed corresponding to the [Ir{(R)-2}2]+ ion. 1H NMR spectroscopic data were 
consistent with the structure shown in Scheme 3.  
 
Scheme 3. Synthetic route to [Ir{(R)-2}2Cl]2, [Ir{(R)-2}2(bpy)]Cl and [Ir{(R)-
4}2(bpy)]Cl. 
 
The reaction of [Ir{(R)-2}2Cl]2 with two equivalents of bpy yielded, after workup, 
yellow [Ir{(R)-2}2(bpy)]Cl in 45.9% yield. The high-resolution ESI-MS exhibited a 
peak envelope at m/z 1293.3535 arising from the [M–Cl]+ ion. The solution 1H and 13C 
NMR spectra (see Figs. S9 and S10) were assigned using 2D methods, and the presence 
of the two diastereoisomers of the [Ir{(R)-2}2(bpy)]+ cation resulted in the appearance of 
1:1 pairs of signals in the 13C NMR spectrum for Cc-CO, CB2, CB5, CA1, CA2, CA4, CA5, 
CA6, CS1, CS2, CS3, CS4, Ca, Cb, Cc, Cc-OAc and CS2-OAc (see experimental section). The 
conversion of [Ir{(R)-2}2(bpy)]Cl to [Ir{(R)-4}2(bpy)]Cl was carried out using NaOMe 
as described above, and this step yielded [Ir{(R)-4}2(bpy)]Cl in 83.5% yield. NMR 
spectra of [Ir{(R)-4}2(bpy)]Cl are shown in Figs. S11 and S12. Loss of the acetyl 
resonances in the 1H and 13C NMR spectra confirmed complete deprotection had 
occurred; the OH groups in [Ir{(R)-4}2(bpy)]Cl gave rise to broad signals at δ 5.03, 4.85 
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and 4.52 ppm. Just as was observed on going from [Ir(ppy)2{(S)-1}]Cl to [Ir(ppy)2{(S)-
3}]Cl in Fig. 2, the 1H NMR resonances for HS1, HS2, HS3, HS4 and Hc/c' shifted to lower 
frequency upon deprotection, albeit with the change in solvent necessitated by the 
different solubility characteristics. 
 
3.3 Electrochemical properties 
The iridium(III) compounds are redox active and their electrochemical behaviour was 
studied by cyclic voltammetry; propylene carbonate was chosen as solvent to permit use 
of a common solvent for all compounds. The electrochemical data are summarized in 
Table 1, and a representative cyclic voltammogram is shown in Fig. 3. Each complex 
undergoes an oxidative process at a potential in the range +0.79 to +0.84 V with respect 
to the Fc/Fc+ couple. These values are similar to the potential (+0.84 V) at which the 
parent complex [Ir(ppy)2(bpy)]+ undergoes a reversible oxidation (in DMF solution) 
[23]. Each complex undergoes a reversible, ligand-centred reduction process within the 
solvent window. As expected, the first reduction is at lower potential when the 
ribofuranose-functionality is attached to the bpy rather than the cyclometallating ligand, 
consistent with the substituent influencing the LUMO of the complex, which is the 
electrochemically addressed energy level.   
 
Table 1. Cyclic voltammetric data referenced to Fc/Fc+; propylene carbonate solutions 
with [nBu4N][PF6] supporting electrolyte, and a scan rate of 0.1 V s–1 (ir = irreversible). 
Compound Eox1/2/V (Epc – Epa/mV) Ered1/2/V (Epc – Epa/mV) ΔE (Eox1/2 –Ered1/2) / V 
[Ir(ppy)2{(R)-1}]Cl +0.80 (70) –1.84 (75) 2.64 
[Ir(ppy)2{(S)-1}]Cl +0.82 (48)  –1.83 (57) 2.65 
[Ir{(R)-2}2(bpy)]Cl +0.84 (ir) –1.75 (74) 2.59 
[Ir(ppy)2{(R)-3}]Cl +0.80 (65) –1.84 (86) 2.64 
[Ir(ppy)2{(S)-3}]Cl +0.79 (66) –1.85 (86) 2.64 
[Ir{(R)-4}2(bpy)]Cl +0.83 (ir) –1.74 (55) 2.57 
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Fig. 3. Cyclic voltammogram of [Ir(ppy)2{(S)-3}]Cl in propylene carbonate with 
[nBu4N][PF6] supporting electrolyte, and scan rate of 0.1 V s–1. Referenced with respect 
to Fc/Fc+. 
 
3.4 Absorption and emission spectroscopic properties 
The solution absorption spectra of the six [Ir(C^N)2(N^N)]Cl complexes are depicted in 
Fig. 4, and values of λmax and εmax are given in the experimental section. The intense 
absorption maxima in the high-energy region arise from spin- and Laporte-allowed C^N 
and N^N ligand-based π*←π transitions. For each of [Ir(ppy)2{(R)-1}]Cl, [Ir(ppy)2{(S)-
1}]Cl, [Ir(ppy)2{(R)-3}]Cl and [Ir(ppy)2{(S)-3}]Cl, the most intense band appears at λmax 
= 255 nm. The change in profile of the absorption spectrum and the gain in a maximum 
at 276 nm on going to [Ir{(R)-2}2(bpy)]Cl and [Ir{(R)-4}2(bpy)]Cl corresponds to 
relocating the ribofuranose-functionality from the bpy to the cyclometallating ligand. 
The absorption bands in the UV region can be partitioned into those characteristic of 
C^N ligand-centred (1LC) transitions (higher energy) and those with larger contributions 
from N^N ligand-based transitions (~280–330 nm) [24,25]. The weak and broad 
absorptions in the visible (425 nm for [Ir(ppy)2{(R)-1}]Cl, [Ir(ppy)2{(S)-1}]Cl, 
[Ir(ppy)2{(R)-3}]Cl and [Ir(ppy)2{(S)-3}]Cl, and 400 nm for [Ir{(R)-2}2(bpy)]Cl and 
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[Ir{(R)-4}2(bpy)]Cl) arise from charge transfer (1MLCT and 1LLCT) transitions. The 
shift from 425 nm for the first series to 400 nm for the second pair of compounds is 
presumably associated with functionalization being on either the C^N (localized on the 
HOMO) or the N^N ligand (localized on the LUMO) [12]. 
 
 
Fig. 4. Solution absorption spectra (in MeOH, 1 × 10–5 mol dm–3) of the 
[Ir(C^N)2(N^N)]Cl complexes. Dotted curves refer to complexes with acetyl-protected 
ligands.  
 
Figure 5 shows the emission spectra of MeOH solutions of the six complexes and 
quantum yields and emission lifetimes for both degassed and non-degassed solutions are 
given in Table 2. The lowest energy triplet state of an [Ir(C^N)2(N^N)]+ complex is the 
emitting state, and broad emission bands (Fig. 5) are indicative of dominant charge-
transfer (3MLCT and 3LLCT) contributions [12]. For each of [Ir(ppy)2{(R)-1}]Cl, 
[Ir(ppy)2{(S)-1}]Cl, [Ir(ppy)2{(R)-3}]Cl and [Ir(ppy)2{(S)-3}]Cl, λemmax is in the range 
571–576 nm. A shift to lower energy is observed on going to [Ir{(R)-2}2(bpy)]Cl and 
[Ir{(R)-4}2(bpy)]Cl, consistent with the electrochemical band-gap, ΔE (Table 1) which 
decreases on going from [Ir(ppy)2(N^N)]Cl (N^N = (R)-1, (S)-1, (R)-3 and (S)-3) to 
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[Ir(C^N)2(bpy)]Cl (C^N = [(R)-2]– and [(R)-4]–). Values of λemmax for the latter two 
complexes (588 and 589 nm) are similar to that of the archetype complex 
[Ir(ppy)2(bpy)]+ (585 nm) [26]. 
  In degassed solution, the photoluminescence QY values for the series of 
complexes are similar and are only slightly lower than the 14% reported for 
[Ir(ppy)2(bpy)][PF6] in deaerated MeCN solution [26]. The introduction of the 
peripheral ribofuranose groups and the positioning on the bpy or ppy moieties has little 
effect on the QY. The emission lifetimes of 228–250 ns (Table 2) compare favourably 
with that of 430 nm for [Ir(ppy)2(bpy)][PF6] (MeCN) [26]. 
 
Table 2. Emission maxima (λemmax), quantum yields (QY) and emission lifetimes (τ1/2) of 
MeOH solutions. 
Complexa λemmax / nm QY / % τ1/2 / ns  
  Non-
degassed 
Degassed Non-
degassed 
Degassed 
[Ir(ppy)2{(R)-1}]Cl 571 3.0 10.3 71 250 
[Ir(ppy)2{(S)-1}]Cl 576 3.0 9.1 70 228 
[Ir{(R)-2}2(bpy)]Cl 588 2.1 7.4 64 236 
[Ir(ppy)2{(R)-3}]Cl 572 2.9 9.3 68 236 
[Ir(ppy)2{(S)-3}]Cl 572 2.8 9.7 68 241 
[Ir{(R)-4}2(bpy)]Cl 589 2.3 7.7 65 233 
a λexc = 280 nm, concentration = 5.0 × 10–6 mol dm–3; lifetime detected at 570 nm for 
[Ir(ppy)2{(R)-1}]Cl, [Ir(ppy)2{(S)-1}]Cl, [Ir(ppy)2{(R)-3}]Cl, [Ir(ppy)2{(S)-3}]Cl and at 590 
nm for [Ir{(R)-2}2(bpy)]Cl and [Ir{(R)-4}2(bpy)]Cl. 
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Fig. 4. Normalized solution emission spectra (in MeOH, 1 × 10–5 mol dm–3) of the 
[Ir(C^N)2(N^N)]Cl complexes (λexc = 380 nm, the small band at 760 nm is the first 
harmonic). Dotted curves refer to complexes with acetyl-protected ligands. 
  
4 Conclusions 
In this paper we have described the preparation and characterization of a series of sugar-
functionalized luminescent complexes based upon an [Ir(C^N)2(N^N)]+ core.  The sugar 
substituents were introduced on both the C^N (Hppy) and N^N (bpy) ligands. The 
successful synthesis of these compounds shows that conjugates incorporating the desired 
functionality can be achieved without developing new strategies. The photophysical and 
electrochemical properties of the [Ir(C^N)2(N^N)]+ core are unaffected and modulation 
through substitution of the C^N and N^N ligands conforms with the expected frontier 
orbital contributions. 
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